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Key points 
• Autocrine TNF-α production by CML stem/progenitor cells (SPCs) is not BCR-ABL 
kinase-dependent and provides survival signals 
• Targeting TNF-α production by CML SPCs might be exploited therapeutically 
especially in combination with tyrosine kinase inhibitors (TKIs) 
Abstract 
Chronic myeloid leukaemia (CML) stem cells are not dependent on BCR-ABL kinase for 
their survival suggesting that kinase-independent mechanisms must contribute to their 
persistence. We observed that CML stem/progenitor cells (SPCs) produce tumour necrosis 
factor-alpha (TNF-α) in a kinase-independent fashion and at higher levels relative to their 
normal counterparts. We therefore investigated the role of TNF-α and found that it supports 
survival of CML SPCs by promoting NFκB/p65 pathway activity and expression of the 
interleukin-3 and granulocyte/macrophage-colony stimulating factor common β-chain 
receptor. Furthermore, we demonstrate that in CML SPCs inhibition of autocrine TNF-α 
signalling via a small molecule TNF-α inhibitor induces apoptosis. Moreover TNF-α 
inhibition combined with nilotinib induces significantly more apoptosis relative to either 
treatment alone and a reduction in the absolute number of primitive quiescent CML stem 
cells. These results highlight a novel survival mechanism of CML SPCs and suggest a new 
putative therapeutic target for their eradication. 
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Introduction 
Disease persistence in chronic phase (CP) chronic myeloid leukaemia (CML) patients on 
tyrosine kinase inhibitor (TKI) therapy is caused by a population of leukaemic stem cells 
(LSCs)1,2 which are not BCR-ABL oncogene addicted3,4, thus highlighting the need to 
identify novel therapeutic targets for their eradication. Autocrine production of interleukin-3 
and granulocyte-colony stimulating factor by CML stem/progenitor cells (SPCs) resulting in 
STAT5 activation and growth factor (GF)-independent growth has been reported suggesting 
that this mechanism is relevant to BCR-ABL induced transformation5. Tumour necrosis 
factor-alpha (TNF-α) is a pleiotropic GF whose role in haemopoiesis is highly dependent on 
cell context, its concentration and the presence of other GFs, with both inhibitory and 
stimulatory effects reported6-8.  Although originally described as cytotoxic to cancer cells 
given its ability to induce apoptosis9, TNF-α is often produced by malignant and immune 
cells present in the inflammatory reaction surrounding tumours10,11. Regardless of its source, 
TNF-α can contribute to tumourigenesis by creating a tumour-supportive inflammatory 
microenvironment and through direct effects on malignant cells12.  A role has already been 
reported for autocrine TNF-α produced by JAK2V617F+ cells in supporting the growth of 
myeloproliferative neoplasm patients’ CD34+ cells, while inhibiting normal CD34+ cell 
growth13. In CML it has been shown that TNF-α concentration is higher in bone marrow 
(BM) supernatants derived from BCR-ABL+ transgenic compared to wild-type mice. 
Moreover LSCs from BCR-ABL+ mice proliferate more compared to wild-type counterparts 
when cultured in the presence of TNF-α at the concentrations detected in the BM of 
leukaemic mice14. More recently, BCR-ABL-mediated upregulation of inflammatory 
pathway receptors (including TNF-α) has been shown to promote CML LSC self-renewal 
through upregulation of p150 isoform of the RNA editing enzyme ADAR115. Here we 
investigated TNF-α production and its putative role as a survival and proliferative signal in 
primary human CML SPCs. 
Materials and methods  
Nilotinib (NL) was supplied by Novartis. The small molecule TNF-α inhibitor16 and human 
recombinant TNF-α were purchased respectively from Merck Chemicals and New England 
BioLabs. Plasma and primary cells were obtained following consent, according to the 
Declaration of Helsinki, from blood and leukapheresis samples of CML and lymphoma 
4 
 
patients without BM involvement as normal controls. CD34+ enrichment, in vitro culture in 
physiologic (for CML cells) or high (for normal cells) GF-supplemented serum-free medium 
and colony-forming cell (CFC) assays were performed as previously described3. Sorting into 
CD34+ CD38- and CD34+ CD38+ cells and detection of BCR-ABL fusion in CD34+ CD38- 
CML cells by fluorescence in situ hybridisation were performed as previously reported17. 
ELISA was carried out using the Invitrogen Human UltraSensitive TNF-α kit (#KHC3014) 
according to the manufacturer’s protocol. Western blotting and flow-cytometry for 
surface/intracellular protein, annexin and carboxyfluorescein succinimidyl ester (CFSE) 
staining with percentage recovery calculations were performed as previously described3,17. 
Quantitative real time-polymerase chain reaction (qRT-PCR) was undertaken using the 
Fluidigm BioMark HD System and TaqMan (Applied Biosystems) gene expression assays as 
per manufacturer’s instructions (list of antibodies and gene expression assays used in 
supplemental materials). Statistical analysis was done by Student t-test for matched samples, 
Mann-Whitney test for unpaired samples and one-way ANOVA with post-hoc testing for 
multiple comparisons.  
Results and discussion 
Having demonstrated that TNF-α plasma levels are consistently higher in CML than normal 
patients’ samples, regardless of disease stage, we investigated TNF-α mRNA expression in a 
large cohort of CML SPCs and found that it was significantly elevated. Although higher in 
CML mononuclear compared to CD34+ cells (as expected given TNF-α is normally produced 
by lymphocytes and macrophages), TNF-α mRNA levels were similar between the CD34+ 
CD38- and CD34+ CD38+ cell fractions (Figure 1A, B and supplemental Figure 1A, B). We 
confirmed this finding at the protein level in a small group of samples and showed that 
autocrine TNF-α production by CML SPCs was not significantly reduced by treatment with 
NL at either the mRNA or protein level, suggesting that it is not under the control of BCR-
ABL kinase (Figure 1C, D and supplemental Figure 1C-E).  
TNF-α’s pleiotropic effects are secondary to its ability to activate both proapoptotic and 
prosurvival signals18. Amongst the latter, the NFκB/p65 transcription factor is particularly 
relevant. Upon NFκB/p65 expression, TNF-α is unable to induce apoptosis because it 
simultaneously activates NFκB/p65 which promotes, amongst others, the expression of the 
inhibitor of apoptosis protein (IAP) family.  IAPs block the proapoptotic caspase-8 activation 
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also induced by TNF-α so that in their presence the net output of TNF-α signalling is to 
promote survival and proliferation of its target cells19,20. IAP2 in particular is directly 
activated by NFκB/p65 and in turn activates it through a positive feedback loop20. CML cells 
express a constitutively active NFκB/p6521 and treatment of CML CD34+ cells with TNF-α 
inhibitor - which promotes subunit disassembly of the TNF-α trimer16- reduced 
phosphorylation levels of NFκB/p65 on the activating serine 53622 (although to a moderate 
extent suggesting residual NFκB/p65 phosphorylation was present possibly due to BCR-ABL 
kinase activity) and of its upstream inhibitor IκBα – which is degraded when 
phosphorylated18 – on serine 32/36. Moreover consistent correlative changes in IAP2 gene 
expression were observed. These effects were rescued by adding TNF-α to the culture (Figure 
1E, F; supplemental Figure 2). TNF-α also exerts stimulatory effects on normal haemopoiesis 
indirectly by inducing interleukin-3 and granulocyte/macrophage-colony stimulating factor 
common β-chain receptor (CSF2RB) expression in normal CD34+ cells23. We observed that 
CSF2RB gene and protein expression were higher in CML relative to normal SPCs and 
downregulated by TNF-α inhibitor, with these effects again rescued by TNF-α (supplemental 
Figure 3). Together these results suggest that autocrine TNF-α could act as a survival and 
proliferative signal in CML CD34+ by inducing NFκB/p65 activity and CSF2RB expression. 
Consistent with this hypothesis, TNF-α inhibitor reduced proliferation and increased 
apoptosis levels in CML CD34+ cells, including within the TKI resistant quiescent (CFSEmax) 
population17,24, with TNF-α again rescuing this phenotype (Figure 1G, H). Similar effects 
were not seen in normal CD34+ cells which express lower/negligible levels of autocrine TNF-
α suggesting that the results observed in CML CD34+ cells were secondary to autocrine TNF-
α inhibition (supplemental Figure 4).  
Because TNF-α production by CML SPCs was not BCR-ABL kinase-dependent and TNF-α 
inhibitor showed no off-target inhibition of BCR-ABL kinase activity (supplemental Figure 
5), we investigated the effects of NL and TNF-α inhibitor in combination on CML SPCs. 
This combination reduced CML CD34+ cells CFC output and induced significantly higher 
levels of apoptosis relative to either treatment alone, including within CFSEmax and CD34+ 
CD38- cells (Figure 2A-E).  Analysis of percentage recovery of starting cells, which relates 
the contribution of input cells to the surviving output cell number following drug treatment,  
confirmed that the NL and TNF-α inhibitor combination resulted in a significant depletion of 
the CFSEmax cells relative to untreated (Figure 2F).  
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These observations support the hypothesis that, similarly to the effects reported in JAK2V617+ 
myeloproliferative neoplasms14, autocrine TNF-α promotes survival and proliferation in 
CML CD34+ cells and that interference with TNF-α production/signalling could be exploited 
therapeutically for their eradication. Moreover as TNF-α acts as a prosurvival signal only in 
the presence of an active NFκB/p65, its autocrine production could also be directed towards  
apoptosis induction by inhibiting NFκB/p65 signals through IAP inhibitors (such as SMAC 
mimetics), as already shown in other cancer models25. A detailed characterisation of the 
effects of autocrine GFs produced by CML SPCs can help identifying novel therapeutic 
targets for their eradication. 
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Figure legends 
Figure 1. Autocrine TNF-α production in CML SPCs is BCR-ABL kinase-independent, 
induces NFκB/p65 activity and promotes their survival  
(A) TNF-α blood plasma levels were measured by ELISA in CP (n=24) and accelerated 
phase (AP) (n=3) CML patients. Levels are expressed as pg/mL. Range of TNF-α blood 
plasma levels in normal controls (n=8) is shown in shaded area. (B) TNF-α mRNA 
expression levels were measured by qRT-PCR and normalised to the control genes ATP5B, 
B2M, ENOX2, GUSB, TBP and TYW1 mRNA expression levels in newly diagnosed CP 
CML (n=30) and normal (n=4) CD34+ cells. (C) TNF-α protein expression was measured by 
intracellular flow-cytometry  in CML (n=6) and normal (n=4) CD34+ cells and expressed as a 
ratio of the mean fluorescence intensity (MFI) of TNF-α antibody stained cells over the MFI 
of cells stained with a matched isotype control. (D) CML CD34+ cells (n=4) were either left 
UT or treated with NL (5µM) for 48 hours and TNF-α protein expression was measured by 
intracellular flow-cytometry as explained in panel C. TNF-α expression levels in the NL 
treated cells were expressed as a percentage of UT. (E) CML CD34+ cells (n=3) were either 
left UT or treated with TNF-α inhibitor (TNF-α inh) (3µM) or TNF-α inh (3μM) + TNF-α 
(1ng/mL). Levels of p-NFκB/p65Ser536 were measured by intracellular flow-cytometry at 24 
hours as described in panel C and expressed as percentage of UT. (F) IAP2 gene expression 
levels were measured at 24 hours by qRT-PCR following treatment as in E. Differences in 
gene expression levels following treatment were calculated using the 2-ΔΔCt method after 
normalisation within each sample of candidate gene expression levels against GAPDH and 
TBP expression levels. Relative quantification (RQ) of TNF-α mRNA expression following 
NL treatment was then plotted as log2 of the 2-ΔΔCt values (with the UT cells having a value of 
0 in the graph being the calibrator). (G) CML CD34+ cells (n=5) were either left UT or 
treated with TNF-α inh (3µM) or TNF-α inh (3μM) + TNF-α (1ng/mL) for 72 hours. 
Percentage of apoptotic cells was measured by annexin staining. (H) CML CD34+ cells (n=3) 
were CFSE stained and then cultured as in panel G for 72 hours. Percentage of apoptotic cells 
within the undivided (CFSEmax) population was measured by gating on the population double 
positive for maximal CFSE expression and annexin staining.  All data from independent 
experiments are presented as mean ± standard error of the mean (SEM). Significance values; 
*, P<0.05; †, P<0.01; ‡, P<0.001; ns, not significant. 
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Figure 2. Effects of autocrine TNF-α inhibition in combination with NL on CML SPCs 
survival and proliferation 
(A) CML CD34+ cells (n=3) were either left UT or treated with TNF-α inh (3µM), NL (5μM) 
or their combination for 72 hours before drug washout and plating in methylcellulose 
progenitor assays. CFC frequency based on their morphology – erythroid-burst forming unit 
(BFU-E) and erythroid- colony forming unit (CFU-E) versus granulocyte/macrophage-colony 
forming unit (CFU-GM) - was recorded after 12 days culture. (B) CML CD34+ cells (n=5) 
were cultured as in panel A for 72 hours and percentage of apoptotic cells was measured by 
annexin staining. (C) CML CD34+ cells (n=4) were CFSE stained and then cultured as in 
panel A for 72 hours. Percentage of apoptotic cells within the undivided (CFSEmax) 
population was measured as explained in Figure 1H. (D) Sorted CML, BCR-ABL+ (by 
fluorescence in situ hybridisation) CD34+ CD38- cells (n=2) were cultured as in panel A for 
72 hours. Percentage of apoptotic cells was measured by annexin staining. (E) Representative 
flow-cytometry plot of CFSE and annexin double staining showing levels of apoptosis within 
the CFSEmax population in each treatment arm. (F) CML CD34+ cells (n=4) were treated for 
72 hours as in panel A and the percentage of starting CD34+ cells recovered within each 
division in each treatment arm was calculated by recording the number of viable cells seeded 
initially in each culture and their number following different treatment conditions and using 
levels of CFSE fluorescence to measure the percentage of cells within each division as 
explained elsewhere17. All data from independent experiments are presented as mean ± SEM. 
Significance values; *, P<0.05; †, P<0.01; ‡, P<0.001.  
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